Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Lee’s Pharmaceutical Enters Exclusive Global Licensing Agreement with Ashlins Ocular for Interferon Alpha-2b Outside Greater China

Fineline Cube Jul 20, 2026
Company Deals

Immvira Bioscience Files for Hong Kong IPO to Advance Novel Oncolytic Immunotherapy and Engineered Exosome Pipeline

Fineline Cube Jul 17, 2026
Company Deals

Eli Lilly to Acquire AtaiBeckley for $3.8 Billion, Accelerating Psychedelic Therapeutics Development for Treatment-Resistant Depression

Fineline Cube Jul 17, 2026
Company Deals

Jasper Therapeutics Completes Acquisition of Kira Pharmaceuticals in All-Stock Transaction, Secures $132M Private Placement for Complement Therapies Pipeline

Fineline Cube Jul 17, 2026
Company Deals

China Resources Pharmaceutical to Acquire 23.5% Stake in Lier Chemical to Advance Synthetic Biology Pipeline

Fineline Cube Jul 16, 2026
Policy / Regulatory

Fujian Province Launches Comprehensive Biomedical Innovation Support Framework with Accelerated Listing, Premium Pricing, and Enhanced Insurance Coverage Mechanisms

Fineline Cube Jul 20, 2026
Company Drug

CanSino Biologics Secures NMPA Acceptance for Menhycia Age Expansion to Adolescents, Extending China’s First Quadrivalent Meningococcal Conjugate Vaccine Coverage to Ages 3 Months–17 Years

Fineline Cube Jul 20, 2026
Company Drug

Easton Pharmaceutical Secures NMPA Approval for China’s First Generic Remimazolam Besylate, Challenging Humanwell’s Ruima Monopoly in Procedural Sedation and General Anesthesia

Fineline Cube Jul 20, 2026
Company Drug

Innovent’s Cyramza Gains NMPA Approval for Hepatocellular Carcinoma

Fineline Cube Oct 10, 2022

Innovent Biologics Inc. (HKG: 1801) has announced that the supplementary Biologic License Application (sBLA) for...

Company Drug

Sciwind Biosciences Initiates US Phase I Study for GLP-1 Agonist XW014

Fineline Cube Oct 10, 2022

China-based Sciwind Biosciences Co., Ltd has announced the initiation and first patient dosing of a...

Company Deals

Fujian Cosunter to Acquire UDCA Capsules Technology from Ruitailai

Fineline Cube Oct 10, 2022

China-based Fujian Cosunter Pharmaceutical Co., Ltd (SHE: 300436) has announced plans to enter into a...

Company Drug

Fujian Cosunter Doses First Patient in Phase I Study of COVID-19 Drug GST-HG171

Fineline Cube Oct 10, 2022

China-based Fujian Cosunter Pharmaceutical Co., Ltd (SHE: 300436) has announced that the first patient has...

Company Drug

Salubris Pharmaceuticals’ First-in-Class Anti-Tumor Drug SAL008 Accepted by NMPA

Fineline Cube Oct 10, 2022

China’s Shenzhen Salubris Pharmaceuticals Co., Ltd (SHE: 002294) has announced that a clinical trial filing...

Company Drug

Roche’s Subcutaneous Herceptin Approved in China for HER2-Positive Breast Cancer

Fineline Cube Oct 10, 2022

Swiss pharmaceutical giant Roche’s (SWX: ROG) Herceptin (trastuzumab, subcutaneous injection) has been approved in China...

Policy / Regulatory

CDE Releases 63rd Batch of Chemical Generic Reference Preparations

Fineline Cube Oct 10, 2022

The Center for Drug Evaluation (CDE) has released the 63rd batch of chemical generic reference...

Policy / Regulatory

Jiangsu Launches Sunshine Procurement Platform for Drugs and Medical Consumables

Fineline Cube Oct 10, 2022

Jiangsu province has launched its drugs and medical consumables sunshine procurement services website, providing a...

Company Drug

Merck’s Keytruda Gains 9th Indication Approval in China for Hepatocellular Carcinoma

Fineline Cube Oct 10, 2022

US major Merck Sharp & Dohme’s (MSD, NYSE: MRK) programmed death-1 (PD-1) inhibitor Keytruda (pembrolizumab)...

Company Deals

Convalife and Jointown Partner for Global Drug Development and Commercialization

Fineline Cube Oct 9, 2022

Shanghai-based Convalife Pharmaceuticals has entered into a strategic partnership with fellow Chinese firm Jointown Pharmaceutical...

Company Drug

Eli Lilly’s Retevmo Wins First China Approvals for RET-Driven Cancers

Fineline Cube Oct 9, 2022

Eli Lilly & Co (NYSE: LLY) has secured its first approvals in China for Retevmo...

Company Deals

VectorBuilder Raises $56.6M in Series C to Expand Life Science R&D

Fineline Cube Oct 9, 2022

Guangzhou-based VectorBuilder, a genetic engineering specialist incubated by the state-owned Guangzhou Industrial Investment and Capital...

Company Policy / Regulatory

WuXi Biologics Removed from US Unverified List Amid Ongoing Restrictions

Fineline Cube Oct 9, 2022

The US Commerce Department’s Bureau of Industry and Security (BIS) has updated its Unverified List...

Company Policy / Regulatory

India Launches Anti-Dumping Investigation Against Chinese Imports of Metronidazole

Fineline Cube Oct 9, 2022

The Union Ministry of Commerce and Industry in India has initiated an anti-dumping investigation into...

Policy / Regulatory

China’s NMPA Proposes Reforms to Enhance Radiopharmaceutical Review and Approval

Fineline Cube Oct 9, 2022

China’s National Medical Products Administration (NMPA) has released a draft proposal titled “Opinions on Reforming...

Company Drug

Ark Biosciences’ Ziresovir Shows Positive Results in Phase III AIRFLO Study for RSV Infection

Fineline Cube Oct 9, 2022

China-headquartered Ark Biosciences has announced positive results from the Phase III AIRFLO study for its...

Company Drug

Pfizer’s Talzenna Shows Positive Results in Phase III TALAPRO-2 Study for mCRPC

Fineline Cube Oct 9, 2022

US-based pharmaceutical giant Pfizer (NYSE: PFE) has announced positive results from the Phase III TALAPRO-2...

Company Drug

Hua Medicine’s Dorzagliatin Approved in China for Type 2 Diabetes

Fineline Cube Oct 9, 2022

China-based Hua Medicine (HKG: 2552) has announced that its Category 1 drug dorzagliatin has been...

Company Drug Medical Device

Allergan Aesthetics Launches Juvederm Volite in China’s Boao Lecheng

Fineline Cube Oct 9, 2022

Allergan Aesthetics, an AbbVie company (NYSE: ABBV), has announced the commercial launch of Juvederm Volite...

Company Deals

Shanghai Lange Medtech Partners with Yantai Desheng for Fish-Derived Rotator Cuff Patch

Fineline Cube Oct 9, 2022

China-based Shanghai Lange Medtech Co., Ltd. has entered into a partnership with compatriot firm Yantai...

Posts pagination

1 … 648 649 650 … 697

Recent updates

  • Fujian Province Launches Comprehensive Biomedical Innovation Support Framework with Accelerated Listing, Premium Pricing, and Enhanced Insurance Coverage Mechanisms
  • China’s NMPA Suspends Medochemie’s Tramadol Hydrochloride Capsules Following Non-Compliant Overseas Inspection and Documentation Failure
  • CanSino Biologics Secures NMPA Acceptance for Menhycia Age Expansion to Adolescents, Extending China’s First Quadrivalent Meningococcal Conjugate Vaccine Coverage to Ages 3 Months–17 Years
  • Lee’s Pharmaceutical Enters Exclusive Global Licensing Agreement with Ashlins Ocular for Interferon Alpha-2b Outside Greater China
  • Easton Pharmaceutical Secures NMPA Approval for China’s First Generic Remimazolam Besylate, Challenging Humanwell’s Ruima Monopoly in Procedural Sedation and General Anesthesia
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Policy / Regulatory

Fujian Province Launches Comprehensive Biomedical Innovation Support Framework with Accelerated Listing, Premium Pricing, and Enhanced Insurance Coverage Mechanisms

Policy / Regulatory

China’s NMPA Suspends Medochemie’s Tramadol Hydrochloride Capsules Following Non-Compliant Overseas Inspection and Documentation Failure

Company Drug

CanSino Biologics Secures NMPA Acceptance for Menhycia Age Expansion to Adolescents, Extending China’s First Quadrivalent Meningococcal Conjugate Vaccine Coverage to Ages 3 Months–17 Years

Company Deals

Lee’s Pharmaceutical Enters Exclusive Global Licensing Agreement with Ashlins Ocular for Interferon Alpha-2b Outside Greater China

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.